BG Medicine (OTCPK:BGMD) - Stock Price, News & Analysis

BGMD Stock Overview

Engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. More details

BGMD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($11)

Latest financial reports are more than a year old

Shares are highly illiquid

BG Medicine, Inc. Competitors

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

DermTech

OTCPK:DMTK.Q

US$35.0

MJ Holdings

OTCPK:MJNE

US$58.0

Price History & Performance

Summary of all time highs, changes and price drops for BG Medicine
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.00013
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	0%
33 Year Change	n/a
5 Year Change	-99.99%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	BGMD	US Life Sciences	US Market
7D	0%	2.4%	1.0%
1Y	0%	3.9%	31.4%

Return vs Industry: BGMD underperformed the US Life Sciences industry which returned 3.9% over the past year.

Return vs Market: BGMD underperformed the US Market which returned 31.4% over the past year.

Price Volatility

Is BGMD's price volatile compared to industry and market?
BGMD volatility
BGMD Average Weekly Movement	n/a
Life Sciences Industry Average Movement	8.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BGMD's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BGMD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	Paul Sohmer	www.bg-medicine.com

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators.

BG Medicine, Inc. Fundamentals Summary

How do BG Medicine's earnings and revenue compare to its market cap?
BGMD fundamental statistics
Market cap	US$11.00
Earnings (TTM)	-US$6.96m
Revenue (TTM)	US$1.57m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is BGMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BGMD income statement (TTM)
Revenue	US$1.57m
Cost of Revenue	US$505.00k
Gross Profit	US$1.06m
Other Expenses	US$8.02m
Earnings	-US$6.96m

Last Reported Earnings

Dec 31, 2015

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did BGMD perform over the long term?

See historical performance and comparison